Shares of French biotechnology firm Abivax jumped 31% in Tuesday trading following the release of new clinical data for its lead drug candidate, obefazimod, which targets inflammatory bowel disease.
The positive update triggered a sharp repricing of the stock, wiping out significant losses incurred earlier in the month when investors had grown skeptical about the trial's prospects.
The market reaction underscores the binary nature of biotech valuations, where single data points can drastically alter investor sentiment.
Abivax’s recovery highlights how quickly capital can return to small-cap healthcare names when clinical milestones are met, reversing previous bearish positioning.
This development adds to a broader theme of volatility and recovery in the European biotech sector.
Recent trading sessions have seen similar swings among peers, including ArgenX, which erased previous losses to drive gains on the Brussels exchange, and Viking Therapeutics, which has seen renewed interest as it advances its obesity drug pipeline.